The global circulating tumor cells (CTC) liquid biopsy market is experiencing significant growth during the forecast period of 2023-2030. The market is driven by the growing demand for CTC liquid biopsy due to its effectiveness in cancer detection and monitoring. The increasing prevalence of cancer, influenced by genetic disorders, lifestyle changes, and alcohol consumption, further boosts the market's growth. The utilization of CTC for patient screening and preclinical studies of cancer drugs adds to its popularity. The introduction of nanotechnology for improved sensitivity and efficiency, widespread adoption of CTC-based liquid biopsy, and rising demand for minimally invasive diagnostic procedures contribute to the market's expansion.
According to Data Bridge Market Research the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market which was USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030.
“Rising prevalence of cancer facilitate market growth”
The rising prevalence of cancer is a major driver of the global circulating tumor cells (CTC) liquid biopsy market. Cancer remains a significant global health concern, with increasing cases reported each year. Liquid biopsies offer a non-invasive and convenient approach for early cancer detection, monitoring treatment response, and assessing disease progression. The ability to capture and analyze CTCs from blood samples provides valuable insights into tumor biology and personalized treatment strategies. As the demand for accurate and efficient cancer diagnostics and monitoring tools grows, the CTC liquid biopsy market is expected to experience significant growth in the coming years.
What restraints the growth of the global circulating tumor cells (CTC) liquid biopsy market?
“The lower sensitivity of certain liquid biopsies”
The lower sensitivity of certain liquid biopsies is a significant restraint of the global circulating tumor cells (CTC) liquid biopsy market. While liquid biopsies offer non-invasive and convenient methods for cancer detection and monitoring, their sensitivity can vary depending on the type and stage of cancer. In some cases, the level of circulating tumor cells in the blood may be too low to be reliably detected, leading to false-negative results. Improving the sensitivity and accuracy of liquid biopsies is crucial to address this limitation and enhance their clinical utility in cancer diagnostics and treatment monitoring.
Segmentation: Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
The circulating tumor cells (CTC) liquid biopsy market is segmented on the basis of technology, application, clinical application, sample type, product, specimen, and end user.
- On the basis of technology, the circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, EX vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation models, microchips, single spiral microchannel, negative selection and immunocytochemical technologies.
- On the basis of application, the circulating tumor cells (CTC) liquid biopsy market is segmented into cancer application, non-cancer applications, non-invasive prenatal testing (NIPT), organ transplantation infectious disease testing.
- On the basis of clinical application, the circulating tumor cells (CTC) liquid biopsy market is segmented into early cancer screening, diagnosis, therapy selection, treatment monitoring, prognosis and recurrence monitoring.
- On the basis of sample type, the circulating tumor cells (CTC) liquid biopsy market is segmented into blood, urine, saliva, cerebrospinal fluid, others.
- On the basis of product, the circulating tumor cells (CTC) liquid biopsy market is segmented into kits and reagents, blood collection tubes, devices or system.
- On the basis of specimen, the circulating tumor cells (CTC) liquid biopsy market is segmented into blood, bone marrow, and other body fluids.
- On the basis of end user, the circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals, and physician laboratories.
Regional Insights: North America dominates the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
North America holds a dominant position in the global circulating tumor cells (CTC) liquid biopsy market, primarily driven by the widespread adoption of liquid biopsy techniques for cancer diagnosis in the region. The rising incidence of cancer cases in the US has contributed significantly to North America's market leadership. The region's advanced healthcare infrastructure and a strong emphasis on early cancer detection and personalized medicine have further bolstered the adoption of liquid biopsy technologies.
Asia Pacific is projected to witness substantial growth during the forecast period from 2023 to 2030. The market's expansion in this region is attributed to various factors, including increasing disposable income, growing awareness about liquid biopsy techniques, and greater adoption of advanced diagnostic technologies in hospitals, clinics, and diagnostic laboratories. Additionally, the rising healthcare expenditure and improved accessibility to hospitals and diagnostic centers are driving the adoption of liquid biopsy methods, further fueling the market's growth in the Asia Pacific.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market
全球循環腫瘤細胞（CTC）液體活檢市場的最新發展
- 2021年11月，Myriad Genetics, Inc.在聖安東尼奧乳癌研討會上公佈了其數據報告，強調了基因檢測在乳癌治療中的價值。這項發展使 Myriad Genetics, Inc. 能夠向市場推出新產品，促進液體活檢市場的成長。
- 2021 年 2 月，Menarini Silicon Biosystems 推出了用於手動富集和染色循環腫瘤細胞的 CellMag 產品線。產品範圍的擴大增強了美納里尼矽生物系統公司的市場地位，預計將對液體活檢市場的成長產生重大影響。
全球循環腫瘤細胞（CTC）液體活檢市場的主要參與者包括：
- QIAGEN（德國）
- Bio-Techne（美國）
- 精準醫療集團股份有限公司（我們）
- Aviva Systems Biological Corporation（美國）
- Biocept公司（美國）
- Fluxion Biosciences, Inc.（美國）
- Greiner Bio-One International GmbH（奧地利）
- Ikonisys（美國）
- Miltenyi Biotec（德國）
- IVDiagnostics（美國）
- BioFluidica（美國）
- Canopus Medical（瑞典）
- Biolidics有限公司（新加坡）
- Creativ MicroTech, Inc.（美國）
- LungLife AI, Inc.（美國）
- Epic Sciences（美國）
- Rarecells Diagnostics（法國）
- ScreenCell（法國）
- 美納里尼矽生物系統公司（美國）
以上是報告中涉及的關鍵參與者，要了解更多全球循環腫瘤細胞 (CTC) 液體活檢市場公司聯繫方式的詳盡列表，請訪問 https://www.databridgemarketresearch.com/contact
研究方法：全球循環腫瘤細胞（CTC）液體切片市場
資料收集和基準年分析是使用具有大樣本量的資料收集模組完成的。使用市場統計和相干模型來分析和估計市場數據。此外，市場佔有率分析和關鍵趨勢分析是市場報告中的主要成功因素。 DBMR 研究團隊使用的關鍵研究方法是資料三角測量，其中涉及資料探勘、資料變數對市場的影響分析以及初步（產業專家）驗證。除此之外，資料模型還包括供應商定位網格、市場時間軸分析、市場概覽和指南、公司定位網格、公司市場份額分析、測量標準、全球與區域以及供應商份額分析。如有進一步疑問，請要求分析師致電。
